Please ensure Javascript is enabled for purposes of website accessibility

Value Stocks

Finding value is all about buying something at a discount to what it’s actually worth. The same is true of value stocks.

Sometimes factors can cause a stock to get beaten down to the point of being undervalued. Value investing is about finding stocks that are worth more than their current share price.

Investment legends like Sir John Templeton, Benjamin Graham and Warren Buffett realized decades before behavioral finance became a respected academic discipline that systematic psychological errors tend to create market inefficiencies. Templeton, Graham and Buffett reasoned that herding behavior (including momentum traders and short-term speculators that chase price trends) and overreaction bias (the tendency of people to overreact to bad news) are strong forces in the market that can push stocks far below their fair value.

Based on these observations, many of the world’s greatest investors look for stocks that are beaten down by the market due to bad news or negative rumors. Benjamin Graham, the father of value investing, constantly searched for companies that once fetched sky-high valuations but that crashed when the companies were unable to deliver on investors’ expectations.

Warren Buffett famously said, “We simply attempt to be fearful when others are greedy and to be greedy only when others are fearful.”

Value investing is about recognizing opportunities, spotting deep discounts and finding the next big turnaround stock. One way some investors measure a company’s value is its price-to-earnings ratio, or P/E. But P/E is a very simplistic measure of a stock’s value. Experts dig deeper, examining a company’s sales, cash flow, dividend, book value, debt levels, historical valuation patterns and more to determine if a stock is undervalued.

To help you find the next turnaround story, Cabot offers both Cabot Value Investor and Cabot Turnaround Letter. Both advisories are intended for investors who place an added emphasis on company fundamentals and undervalued opportunities.

Value Stocks Post Archives
Five months ago, Allergan (AGN) was an undervalued stock with tons of growth potential. It has since grown a lot—and there’s plenty more upside.
Canadian stocks are a good way to diversify your portfolio without taking on too much risk. And here’s one Canadian stock that appears quite undervalued.
Another Fed rate hike is on the near horizon. Before it happens, you should buy these three stocks in this red-hot sector.
For the past five years, AMZN stock and FB stock have been two of the market’s great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.
The following undervalued stock is a multi-industry holding company that’s going through an aggressive earnings growth phase.
After a rough year, Chipotle stock is back, catching the attention of activist investor Bill Ackman. Will the rally last?
When looking for undervalued stocks, you want to companies with good growth prospects too. Here are 10 that fit that bill.
It isn’t a self-driving car or an internet start-up, but this boring retailer is an undervalued stock with tons of upside.
A year ago I wrote why you should sell Apple (AAPL) stock. It has fallen quite a bit since, but I still think there’s more downside ahead. Here’s why.
One market leader in the hyper-competitive semiconductor industry has become a wildly undervalued stock. And the chart suggests it’s primed for a big breakout.
Sometimes a company undergoes a metamorphosis—like tadpole to frog, or caterpillar to butterfly—and it takes the stock market a while to understand that it’s dealing with a new entity.
There are plenty of undervalued stocks in the financial sector, and this out-of-favor big bank is well positioned for a huge bounce back.
Standard & Poor’s lists a whopping 196 biotechnology companies in its database, but AbbVie (ABBV) stands out above the rest. The company is growing rapidly but due to the correction in biotech stocks, it’s now an undervalued stock.
Mere weeks after its failed merger with Pfizer (PFE), global pharmaceutical company Allergan PLC (AGN), maker of Viagra and Botox, announced a new $10 billion share repurchase authorization. Allergan plans to complete the $40 billion sale of its generic pharmaceutical business to Teva Pharmaceuticals by the end of this month. Following that, Allergan plans to immediately repurchase $4 billion to $5 billion of its stock over the subsequent four to six months. The company also plans to pay down debt with the proceeds of the Teva transaction. Let’s look at the stock’s valuation to see if it’s worth investing in.
Everyone knows Warren Buffett. As the dean of value investing in the U.S, the Chairman and CEO of Berkshire Hathaway (BRK-B) draws thousands of people to his annual meetings in Omaha. As the world’s greatest investor, Warren Buffett seemingly has it all. But there’s one major advantage you have over the Oracle of Omaha.